VISEN Pharmaceuticals (HK:2561)
:2561
2561 Stock Chart & Stats
HK$33.68
--
Market closed
HK$33.68
--
Day’s Range― - ―
52-Week RangeHK$24.00 - HK$54.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)37.57K
Market Cap
HK$2.82B
Enterprise ValueHK$1.57B
Total Cash (Recent Filing)HK$805.91M
Total Debt (Recent Filing)HK$1.20M
Price to Earnings (P/E)―
Beta1.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,926,865
10 Day Avg. Volume36,930
30 Day Avg. Volume37,566
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)25.08
Price to Sales (P/S)2178.79
P/FCF Ratio-42.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe company's ability to achieve positive revenue growth indicates successful market penetration and product acceptance, which is crucial for long-term sustainability.
Low LeverageLow leverage provides financial flexibility and reduces risk, allowing the company to invest in growth opportunities without significant debt burden.
Partnerships And CollaborationsStrategic partnerships expand market reach and innovation capacity, strengthening competitive position and supporting long-term growth prospects.
Bears Say
Profitability ChallengesOngoing profitability challenges can hinder reinvestment in R&D and limit competitive positioning, affecting long-term viability.
Cash Flow IssuesNegative cash flow indicates potential liquidity constraints, which can impact operational efficiency and limit strategic investments.
Operational InefficienciesPersistent operational inefficiencies can lead to higher costs and reduced margins, challenging the company's ability to achieve sustainable profitability.
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$24.00 and its highest was HK$54.00 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$2.82B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VISEN Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People's Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare. The company was incorporated in 2018 and is headquartered in Suzhou, China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Broncus Holding Corp.
―
Sinohealth Holdings Ltd.
―
SinoMab Bioscience Ltd.
―
Town Health International Medical Group Ltd.
―